Why the study?
Metformin is associated with a decreased risk of AF in patients with type 2 diabetes, but the specific underlying mechanism remains unknown.
Does metformin prevent lipid metabolic remodeling in a canine model of atrial fibrillation?
Comparison
SR vs ARP vs ARP plus MET
Design
Preclinical animal study
Authors
Loading...
Metformin modulates atrial FA metabolism via AMPK in canine AF; leaves open whether this translates to human AF prevention.
Does metformin prevent lipid metabolic remodeling in a canine model of atrial fibrillation?
Metformin reduces lipid accumulation and promotes fatty acid β-oxidation in a canine model of atrial fibrillation, suggesting a mechanism for its protective effects against AF.
Bai et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: